nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Ileus paralytic—Vinblastine—head and neck cancer	0.0299	0.03	CcSEcCtD
Naltrexone—Angina unstable—Docetaxel—head and neck cancer	0.0243	0.0243	CcSEcCtD
Naltrexone—Platelet count decreased—Hydroxyurea—head and neck cancer	0.0198	0.0199	CcSEcCtD
Naltrexone—Hepatotoxicity—Hydroxyurea—head and neck cancer	0.0153	0.0153	CcSEcCtD
Naltrexone—Cellulitis—Vinblastine—head and neck cancer	0.0142	0.0143	CcSEcCtD
Naltrexone—Chest tightness—Docetaxel—head and neck cancer	0.0131	0.0131	CcSEcCtD
Naltrexone—Hepatic enzyme increased—Hydroxyurea—head and neck cancer	0.0125	0.0125	CcSEcCtD
Naltrexone—Ulcer—Hydroxyurea—head and neck cancer	0.0125	0.0125	CcSEcCtD
Naltrexone—Phlebitis—Vinblastine—head and neck cancer	0.0109	0.0109	CcSEcCtD
Naltrexone—Haemorrhoids—Docetaxel—head and neck cancer	0.0104	0.0104	CcSEcCtD
Naltrexone—Deep vein thrombosis—Docetaxel—head and neck cancer	0.0101	0.0101	CcSEcCtD
Naltrexone—Disorientation—Hydroxyurea—head and neck cancer	0.00958	0.00959	CcSEcCtD
Naltrexone—Cellulitis—Fluorouracil—head and neck cancer	0.00934	0.00936	CcSEcCtD
Naltrexone—Pharyngolaryngeal pain—Docetaxel—head and neck cancer	0.00908	0.0091	CcSEcCtD
Naltrexone—Laryngeal pain—Docetaxel—head and neck cancer	0.00899	0.00901	CcSEcCtD
Naltrexone—Ulcer—Fluorouracil—head and neck cancer	0.00898	0.00899	CcSEcCtD
Naltrexone—Throat sore—Docetaxel—head and neck cancer	0.00851	0.00852	CcSEcCtD
Naltrexone—Oropharyngeal discomfort—Docetaxel—head and neck cancer	0.00843	0.00844	CcSEcCtD
Naltrexone—Face oedema—Hydroxyurea—head and neck cancer	0.00827	0.00828	CcSEcCtD
Naltrexone—Hepatotoxicity—Docetaxel—head and neck cancer	0.00794	0.00795	CcSEcCtD
Naltrexone—Angina pectoris—Vinblastine—head and neck cancer	0.00791	0.00792	CcSEcCtD
Naltrexone—Rhinorrhoea—Docetaxel—head and neck cancer	0.00757	0.00758	CcSEcCtD
Naltrexone—Rigors—Docetaxel—head and neck cancer	0.00751	0.00752	CcSEcCtD
Naltrexone—Euphoric mood—Fluorouracil—head and neck cancer	0.0073	0.00731	CcSEcCtD
Naltrexone—Depression—Vinblastine—head and neck cancer	0.00722	0.00723	CcSEcCtD
Naltrexone—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00714	0.00715	CcSEcCtD
Naltrexone—Myocardial infarction—Vinblastine—head and neck cancer	0.00709	0.00711	CcSEcCtD
Naltrexone—Swelling—Fluorouracil—head and neck cancer	0.00699	0.007	CcSEcCtD
Naltrexone—Chest discomfort—Docetaxel—head and neck cancer	0.00693	0.00694	CcSEcCtD
Naltrexone—Disorientation—Fluorouracil—head and neck cancer	0.00689	0.0069	CcSEcCtD
Naltrexone—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00674	0.00675	CcSEcCtD
Naltrexone—Weight increased—Hydroxyurea—head and neck cancer	0.00674	0.00675	CcSEcCtD
Naltrexone—Infestation NOS—Hydroxyurea—head and neck cancer	0.0066	0.00661	CcSEcCtD
Naltrexone—Infestation—Hydroxyurea—head and neck cancer	0.0066	0.00661	CcSEcCtD
Naltrexone—Pharyngitis—Vinblastine—head and neck cancer	0.00645	0.00646	CcSEcCtD
Naltrexone—Lethargy—Fluorouracil—head and neck cancer	0.00629	0.0063	CcSEcCtD
Naltrexone—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00624	0.00625	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00617	0.00618	CcSEcCtD
Naltrexone—Pulmonary embolism—Docetaxel—head and neck cancer	0.00613	0.00614	CcSEcCtD
Naltrexone—Blood pressure increased—Docetaxel—head and neck cancer	0.00613	0.00614	CcSEcCtD
Naltrexone—Injection site reaction—Docetaxel—head and neck cancer	0.00609	0.0061	CcSEcCtD
Naltrexone—Hallucination—Hydroxyurea—head and neck cancer	0.0059	0.00591	CcSEcCtD
Naltrexone—Colitis—Docetaxel—head and neck cancer	0.00589	0.0059	CcSEcCtD
Naltrexone—Irritability—Fluorouracil—head and neck cancer	0.00588	0.00589	CcSEcCtD
Naltrexone—Alopecia—Vinblastine—head and neck cancer	0.00574	0.00575	CcSEcCtD
Naltrexone—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00551	0.00552	CcSEcCtD
Naltrexone—Angiopathy—Hydroxyurea—head and neck cancer	0.00538	0.00539	CcSEcCtD
Naltrexone—Chills—Hydroxyurea—head and neck cancer	0.00532	0.00533	CcSEcCtD
Naltrexone—Ill-defined disorder—Vinblastine—head and neck cancer	0.00525	0.00526	CcSEcCtD
Naltrexone—Alopecia—Hydroxyurea—head and neck cancer	0.00524	0.00524	CcSEcCtD
Naltrexone—Angina pectoris—Fluorouracil—head and neck cancer	0.00519	0.0052	CcSEcCtD
Naltrexone—Phlebitis—Docetaxel—head and neck cancer	0.00517	0.00517	CcSEcCtD
Naltrexone—Malaise—Vinblastine—head and neck cancer	0.0051	0.00511	CcSEcCtD
Naltrexone—Swelling—Docetaxel—head and neck cancer	0.00504	0.00505	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00495	0.00496	CcSEcCtD
Naltrexone—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00491	0.00492	CcSEcCtD
Naltrexone—Convulsion—Vinblastine—head and neck cancer	0.0049	0.00491	CcSEcCtD
Naltrexone—Hypertension—Vinblastine—head and neck cancer	0.00488	0.00489	CcSEcCtD
Naltrexone—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00479	0.00479	CcSEcCtD
Naltrexone—Pneumonia—Fluorouracil—head and neck cancer	0.00478	0.00479	CcSEcCtD
Naltrexone—Discomfort—Vinblastine—head and neck cancer	0.00476	0.00477	CcSEcCtD
Naltrexone—Hot flush—Docetaxel—head and neck cancer	0.00476	0.00476	CcSEcCtD
Naltrexone—Infestation NOS—Fluorouracil—head and neck cancer	0.00475	0.00476	CcSEcCtD
Naltrexone—Infestation—Fluorouracil—head and neck cancer	0.00475	0.00476	CcSEcCtD
Naltrexone—Menopausal symptoms—Docetaxel—head and neck cancer	0.00472	0.00472	CcSEcCtD
Naltrexone—Atrial fibrillation—Docetaxel—head and neck cancer	0.0047	0.0047	CcSEcCtD
Naltrexone—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00468	0.00469	CcSEcCtD
Naltrexone—Myocardial infarction—Fluorouracil—head and neck cancer	0.00466	0.00467	CcSEcCtD
Naltrexone—Malaise—Hydroxyurea—head and neck cancer	0.00465	0.00466	CcSEcCtD
Naltrexone—Conjunctivitis—Fluorouracil—head and neck cancer	0.00462	0.00463	CcSEcCtD
Naltrexone—Urinary tract infection—Fluorouracil—head and neck cancer	0.00462	0.00463	CcSEcCtD
Naltrexone—Lethargy—Docetaxel—head and neck cancer	0.00454	0.00455	CcSEcCtD
Naltrexone—Epistaxis—Fluorouracil—head and neck cancer	0.00448	0.00449	CcSEcCtD
Naltrexone—Convulsion—Hydroxyurea—head and neck cancer	0.00447	0.00448	CcSEcCtD
Naltrexone—Sinusitis—Fluorouracil—head and neck cancer	0.00446	0.00446	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00445	0.00446	CcSEcCtD
Naltrexone—Pain in extremity—Docetaxel—head and neck cancer	0.00445	0.00446	CcSEcCtD
Naltrexone—Anorexia—Vinblastine—head and neck cancer	0.0044	0.00441	CcSEcCtD
Naltrexone—Migraine—Docetaxel—head and neck cancer	0.00438	0.00439	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00436	0.00437	CcSEcCtD
Naltrexone—Discomfort—Hydroxyurea—head and neck cancer	0.00434	0.00435	CcSEcCtD
Naltrexone—Pharyngitis—Fluorouracil—head and neck cancer	0.00423	0.00424	CcSEcCtD
Naltrexone—Oedema—Hydroxyurea—head and neck cancer	0.00421	0.00422	CcSEcCtD
Naltrexone—Infection—Hydroxyurea—head and neck cancer	0.00418	0.00419	CcSEcCtD
Naltrexone—Paraesthesia—Vinblastine—head and neck cancer	0.00415	0.00415	CcSEcCtD
Naltrexone—Dehydration—Docetaxel—head and neck cancer	0.00414	0.00415	CcSEcCtD
Naltrexone—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00413	0.00414	CcSEcCtD
Naltrexone—Skin disorder—Hydroxyurea—head and neck cancer	0.00409	0.0041	CcSEcCtD
Naltrexone—Abdominal pain upper—Docetaxel—head and neck cancer	0.00406	0.00407	CcSEcCtD
Naltrexone—Anorexia—Hydroxyurea—head and neck cancer	0.00401	0.00402	CcSEcCtD
Naltrexone—Decreased appetite—Vinblastine—head and neck cancer	0.00401	0.00402	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00401	0.00401	CcSEcCtD
Naltrexone—Cramp muscle—Docetaxel—head and neck cancer	0.00401	0.00401	CcSEcCtD
Naltrexone—Nasopharyngitis—Docetaxel—head and neck cancer	0.00398	0.00399	CcSEcCtD
Naltrexone—Pain—Vinblastine—head and neck cancer	0.00395	0.00395	CcSEcCtD
Naltrexone—Constipation—Vinblastine—head and neck cancer	0.00395	0.00395	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00392	0.00393	CcSEcCtD
Naltrexone—Feeling abnormal—Vinblastine—head and neck cancer	0.0038	0.00381	CcSEcCtD
Naltrexone—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00377	0.00378	CcSEcCtD
Naltrexone—Alopecia—Fluorouracil—head and neck cancer	0.00377	0.00378	CcSEcCtD
Naltrexone—Dyspnoea—Hydroxyurea—head and neck cancer	0.00375	0.00376	CcSEcCtD
Naltrexone—Angina pectoris—Docetaxel—head and neck cancer	0.00375	0.00375	CcSEcCtD
Naltrexone—Somnolence—Hydroxyurea—head and neck cancer	0.00374	0.00375	CcSEcCtD
Naltrexone—Decreased appetite—Hydroxyurea—head and neck cancer	0.00366	0.00367	CcSEcCtD
Naltrexone—Abdominal pain—Vinblastine—head and neck cancer	0.00365	0.00366	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00363	0.00364	CcSEcCtD
Naltrexone—Fatigue—Hydroxyurea—head and neck cancer	0.00363	0.00364	CcSEcCtD
Naltrexone—Pain—Hydroxyurea—head and neck cancer	0.0036	0.00361	CcSEcCtD
Naltrexone—Constipation—Hydroxyurea—head and neck cancer	0.0036	0.00361	CcSEcCtD
Naltrexone—Weight increased—Docetaxel—head and neck cancer	0.0035	0.00351	CcSEcCtD
Naltrexone—Vision blurred—Fluorouracil—head and neck cancer	0.0035	0.00351	CcSEcCtD
Naltrexone—Weight decreased—Docetaxel—head and neck cancer	0.00348	0.00349	CcSEcCtD
Naltrexone—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00347	0.00347	CcSEcCtD
Naltrexone—Pneumonia—Docetaxel—head and neck cancer	0.00345	0.00345	CcSEcCtD
Naltrexone—Infestation NOS—Docetaxel—head and neck cancer	0.00343	0.00343	CcSEcCtD
Naltrexone—Infestation—Docetaxel—head and neck cancer	0.00343	0.00343	CcSEcCtD
Naltrexone—Hypersensitivity—Vinblastine—head and neck cancer	0.0034	0.00341	CcSEcCtD
Naltrexone—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00338	0.00339	CcSEcCtD
Naltrexone—Myocardial infarction—Docetaxel—head and neck cancer	0.00336	0.00337	CcSEcCtD
Naltrexone—Conjunctivitis—Docetaxel—head and neck cancer	0.00333	0.00334	CcSEcCtD
Naltrexone—Body temperature increased—Hydroxyurea—head and neck cancer	0.00333	0.00333	CcSEcCtD
Naltrexone—Asthenia—Vinblastine—head and neck cancer	0.00331	0.00332	CcSEcCtD
Naltrexone—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00324	0.00325	CcSEcCtD
Naltrexone—Epistaxis—Docetaxel—head and neck cancer	0.00323	0.00324	CcSEcCtD
Naltrexone—Convulsion—Fluorouracil—head and neck cancer	0.00322	0.00322	CcSEcCtD
Naltrexone—Myalgia—Fluorouracil—head and neck cancer	0.00316	0.00317	CcSEcCtD
Naltrexone—Chest pain—Fluorouracil—head and neck cancer	0.00316	0.00317	CcSEcCtD
Naltrexone—Diarrhoea—Vinblastine—head and neck cancer	0.00316	0.00316	CcSEcCtD
Naltrexone—Discomfort—Fluorouracil—head and neck cancer	0.00312	0.00313	CcSEcCtD
Naltrexone—Hypersensitivity—Hydroxyurea—head and neck cancer	0.0031	0.00311	CcSEcCtD
Naltrexone—Hepatitis—Docetaxel—head and neck cancer	0.00308	0.00308	CcSEcCtD
Naltrexone—Confusional state—Fluorouracil—head and neck cancer	0.00306	0.00306	CcSEcCtD
Naltrexone—Pharyngitis—Docetaxel—head and neck cancer	0.00306	0.00306	CcSEcCtD
Naltrexone—Dizziness—Vinblastine—head and neck cancer	0.00305	0.00306	CcSEcCtD
Naltrexone—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00303	0.00304	CcSEcCtD
Naltrexone—Oedema—Fluorouracil—head and neck cancer	0.00303	0.00304	CcSEcCtD
Naltrexone—Connective tissue disorder—Docetaxel—head and neck cancer	0.00303	0.00303	CcSEcCtD
Naltrexone—Asthenia—Hydroxyurea—head and neck cancer	0.00302	0.00303	CcSEcCtD
Naltrexone—Infection—Fluorouracil—head and neck cancer	0.00301	0.00302	CcSEcCtD
Naltrexone—Nervous system disorder—Fluorouracil—head and neck cancer	0.00297	0.00298	CcSEcCtD
Naltrexone—Tachycardia—Fluorouracil—head and neck cancer	0.00296	0.00296	CcSEcCtD
Naltrexone—Vomiting—Vinblastine—head and neck cancer	0.00294	0.00294	CcSEcCtD
Naltrexone—Headache—Vinblastine—head and neck cancer	0.00289	0.0029	CcSEcCtD
Naltrexone—Anorexia—Fluorouracil—head and neck cancer	0.00289	0.00289	CcSEcCtD
Naltrexone—Diarrhoea—Hydroxyurea—head and neck cancer	0.00288	0.00289	CcSEcCtD
Naltrexone—Eye disorder—Docetaxel—head and neck cancer	0.00288	0.00288	CcSEcCtD
Naltrexone—Cardiac disorder—Docetaxel—head and neck cancer	0.00286	0.00286	CcSEcCtD
Naltrexone—Angiopathy—Docetaxel—head and neck cancer	0.00279	0.0028	CcSEcCtD
Naltrexone—Dizziness—Hydroxyurea—head and neck cancer	0.00278	0.00279	CcSEcCtD
Naltrexone—Immune system disorder—Docetaxel—head and neck cancer	0.00278	0.00279	CcSEcCtD
Naltrexone—Mediastinal disorder—Docetaxel—head and neck cancer	0.00277	0.00278	CcSEcCtD
Naltrexone—Chills—Docetaxel—head and neck cancer	0.00276	0.00277	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00276	0.00277	CcSEcCtD
Naltrexone—Nausea—Vinblastine—head and neck cancer	0.00274	0.00275	CcSEcCtD
Naltrexone—Insomnia—Fluorouracil—head and neck cancer	0.00274	0.00275	CcSEcCtD
Naltrexone—Paraesthesia—Fluorouracil—head and neck cancer	0.00272	0.00273	CcSEcCtD
Naltrexone—Alopecia—Docetaxel—head and neck cancer	0.00272	0.00272	CcSEcCtD
Naltrexone—Dyspnoea—Fluorouracil—head and neck cancer	0.0027	0.00271	CcSEcCtD
Naltrexone—Mental disorder—Docetaxel—head and neck cancer	0.0027	0.0027	CcSEcCtD
Naltrexone—Somnolence—Fluorouracil—head and neck cancer	0.00269	0.0027	CcSEcCtD
Naltrexone—Malnutrition—Docetaxel—head and neck cancer	0.00268	0.00268	CcSEcCtD
Naltrexone—Vomiting—Hydroxyurea—head and neck cancer	0.00268	0.00268	CcSEcCtD
Naltrexone—Rash—Hydroxyurea—head and neck cancer	0.00265	0.00266	CcSEcCtD
Naltrexone—Dermatitis—Hydroxyurea—head and neck cancer	0.00265	0.00266	CcSEcCtD
Naltrexone—Headache—Hydroxyurea—head and neck cancer	0.00264	0.00264	CcSEcCtD
Naltrexone—Decreased appetite—Fluorouracil—head and neck cancer	0.00263	0.00264	CcSEcCtD
Naltrexone—Dysgeusia—Docetaxel—head and neck cancer	0.00262	0.00263	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00262	0.00262	CcSEcCtD
Naltrexone—Back pain—Docetaxel—head and neck cancer	0.00259	0.0026	CcSEcCtD
Naltrexone—Pain—Fluorouracil—head and neck cancer	0.00259	0.0026	CcSEcCtD
Naltrexone—Muscle spasms—Docetaxel—head and neck cancer	0.00258	0.00258	CcSEcCtD
Naltrexone—Nausea—Hydroxyurea—head and neck cancer	0.0025	0.0025	CcSEcCtD
Naltrexone—Feeling abnormal—Fluorouracil—head and neck cancer	0.0025	0.0025	CcSEcCtD
Naltrexone—Urticaria—Fluorouracil—head and neck cancer	0.00241	0.00241	CcSEcCtD
Naltrexone—Syncope—Docetaxel—head and neck cancer	0.0024	0.00241	CcSEcCtD
Naltrexone—Body temperature increased—Fluorouracil—head and neck cancer	0.0024	0.0024	CcSEcCtD
Naltrexone—Palpitations—Docetaxel—head and neck cancer	0.00237	0.00237	CcSEcCtD
Naltrexone—Loss of consciousness—Docetaxel—head and neck cancer	0.00236	0.00236	CcSEcCtD
Naltrexone—Cough—Docetaxel—head and neck cancer	0.00234	0.00234	CcSEcCtD
Naltrexone—Convulsion—Docetaxel—head and neck cancer	0.00232	0.00233	CcSEcCtD
Naltrexone—Hypertension—Docetaxel—head and neck cancer	0.00231	0.00232	CcSEcCtD
Naltrexone—Myalgia—Docetaxel—head and neck cancer	0.00228	0.00229	CcSEcCtD
Naltrexone—Arthralgia—Docetaxel—head and neck cancer	0.00228	0.00229	CcSEcCtD
Naltrexone—Chest pain—Docetaxel—head and neck cancer	0.00228	0.00229	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00227	0.00227	CcSEcCtD
Naltrexone—Hypersensitivity—Fluorouracil—head and neck cancer	0.00223	0.00224	CcSEcCtD
Naltrexone—Dry mouth—Docetaxel—head and neck cancer	0.00223	0.00224	CcSEcCtD
Naltrexone—Confusional state—Docetaxel—head and neck cancer	0.00221	0.00221	CcSEcCtD
Naltrexone—Anaphylactic shock—Docetaxel—head and neck cancer	0.00219	0.00219	CcSEcCtD
Naltrexone—Oedema—Docetaxel—head and neck cancer	0.00219	0.00219	CcSEcCtD
Naltrexone—Infection—Docetaxel—head and neck cancer	0.00217	0.00218	CcSEcCtD
Naltrexone—Shock—Docetaxel—head and neck cancer	0.00215	0.00216	CcSEcCtD
Naltrexone—Nervous system disorder—Docetaxel—head and neck cancer	0.00214	0.00215	CcSEcCtD
Naltrexone—Pruritus—Fluorouracil—head and neck cancer	0.00214	0.00215	CcSEcCtD
Naltrexone—Tachycardia—Docetaxel—head and neck cancer	0.00213	0.00214	CcSEcCtD
Naltrexone—Skin disorder—Docetaxel—head and neck cancer	0.00212	0.00213	CcSEcCtD
Naltrexone—Anorexia—Docetaxel—head and neck cancer	0.00208	0.00209	CcSEcCtD
Naltrexone—Diarrhoea—Fluorouracil—head and neck cancer	0.00207	0.00208	CcSEcCtD
Naltrexone—Dizziness—Fluorouracil—head and neck cancer	0.002	0.00201	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00199	0.002	CcSEcCtD
Naltrexone—Insomnia—Docetaxel—head and neck cancer	0.00198	0.00198	CcSEcCtD
Naltrexone—Paraesthesia—Docetaxel—head and neck cancer	0.00196	0.00197	CcSEcCtD
Naltrexone—Dyspnoea—Docetaxel—head and neck cancer	0.00195	0.00195	CcSEcCtD
Naltrexone—Somnolence—Docetaxel—head and neck cancer	0.00194	0.00195	CcSEcCtD
Naltrexone—Vomiting—Fluorouracil—head and neck cancer	0.00193	0.00193	CcSEcCtD
Naltrexone—Rash—Fluorouracil—head and neck cancer	0.00191	0.00191	CcSEcCtD
Naltrexone—Dermatitis—Fluorouracil—head and neck cancer	0.00191	0.00191	CcSEcCtD
Naltrexone—Decreased appetite—Docetaxel—head and neck cancer	0.0019	0.0019	CcSEcCtD
Naltrexone—Headache—Fluorouracil—head and neck cancer	0.0019	0.0019	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00189	0.00189	CcSEcCtD
Naltrexone—Fatigue—Docetaxel—head and neck cancer	0.00189	0.00189	CcSEcCtD
Naltrexone—Pain—Docetaxel—head and neck cancer	0.00187	0.00187	CcSEcCtD
Naltrexone—Constipation—Docetaxel—head and neck cancer	0.00187	0.00187	CcSEcCtD
Naltrexone—Feeling abnormal—Docetaxel—head and neck cancer	0.0018	0.00181	CcSEcCtD
Naltrexone—Nausea—Fluorouracil—head and neck cancer	0.0018	0.0018	CcSEcCtD
Naltrexone—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00179	0.00179	CcSEcCtD
Naltrexone—Abdominal pain—Docetaxel—head and neck cancer	0.00173	0.00173	CcSEcCtD
Naltrexone—Body temperature increased—Docetaxel—head and neck cancer	0.00173	0.00173	CcSEcCtD
Naltrexone—Hypersensitivity—Docetaxel—head and neck cancer	0.00161	0.00161	CcSEcCtD
Naltrexone—Asthenia—Docetaxel—head and neck cancer	0.00157	0.00157	CcSEcCtD
Naltrexone—Pruritus—Docetaxel—head and neck cancer	0.00155	0.00155	CcSEcCtD
Naltrexone—Diarrhoea—Docetaxel—head and neck cancer	0.0015	0.0015	CcSEcCtD
Naltrexone—Dizziness—Docetaxel—head and neck cancer	0.00145	0.00145	CcSEcCtD
Naltrexone—Vomiting—Docetaxel—head and neck cancer	0.00139	0.00139	CcSEcCtD
Naltrexone—Rash—Docetaxel—head and neck cancer	0.00138	0.00138	CcSEcCtD
Naltrexone—Dermatitis—Docetaxel—head and neck cancer	0.00138	0.00138	CcSEcCtD
Naltrexone—Headache—Docetaxel—head and neck cancer	0.00137	0.00137	CcSEcCtD
Naltrexone—Nausea—Docetaxel—head and neck cancer	0.0013	0.0013	CcSEcCtD
Naltrexone—UGT1A1—Porphyrin metabolism—UROD—head and neck cancer	0.000375	0.227	CbGpPWpGaD
Naltrexone—UGT1A1—Estrogen metabolism—GSTM1—head and neck cancer	7.34e-05	0.0445	CbGpPWpGaD
Naltrexone—UGT1A1—Estrogen metabolism—CYP1A1—head and neck cancer	6.96e-05	0.0422	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—STAT6—head and neck cancer	5.08e-05	0.0308	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—NAT2—head and neck cancer	4.17e-05	0.0253	CbGpPWpGaD
Naltrexone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	3.75e-05	0.0227	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—KISS1—head and neck cancer	3.5e-05	0.0212	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	3.28e-05	0.0199	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—KISS1—head and neck cancer	3.07e-05	0.0186	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—GRP—head and neck cancer	2.88e-05	0.0175	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—KISS1—head and neck cancer	2.59e-05	0.0157	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—GRP—head and neck cancer	2.53e-05	0.0153	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—NAT2—head and neck cancer	2.44e-05	0.0148	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—NAT2—head and neck cancer	2.41e-05	0.0146	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—TGFA—head and neck cancer	2.37e-05	0.0144	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	2.35e-05	0.0142	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—BCL2L1—head and neck cancer	2.26e-05	0.0137	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—GRP—head and neck cancer	2.14e-05	0.0129	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—GSTM1—head and neck cancer	2.06e-05	0.0125	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	2.06e-05	0.0125	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	1.93e-05	0.0117	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	1.81e-05	0.011	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—KISS1—head and neck cancer	1.79e-05	0.0108	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	1.74e-05	0.0105	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	1.7e-05	0.0103	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—KISS1—head and neck cancer	1.57e-05	0.0095	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—GRP—head and neck cancer	1.47e-05	0.00892	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	1.43e-05	0.00869	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	1.38e-05	0.00839	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—GSTM1—head and neck cancer	1.38e-05	0.00834	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—KISS1—head and neck cancer	1.32e-05	0.00803	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—GRP—head and neck cancer	1.29e-05	0.00783	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—GSTM1—head and neck cancer	1.21e-05	0.00731	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—GSTM1—head and neck cancer	1.19e-05	0.00721	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—CYP1A1—head and neck cancer	1.14e-05	0.00693	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—CYP1A1—head and neck cancer	1.13e-05	0.00684	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—GRP—head and neck cancer	1.09e-05	0.00661	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—KISS1—head and neck cancer	1.01e-05	0.00612	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—UROD—head and neck cancer	1.01e-05	0.0061	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	9.42e-06	0.00571	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—PIK3CA—head and neck cancer	9.25e-06	0.00561	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KISS1—head and neck cancer	9.17e-06	0.00556	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—KISS1—head and neck cancer	8.86e-06	0.00537	CbGpPWpGaD
Naltrexone—OPRM1—Opioid Signalling—MAPK1—head and neck cancer	8.61e-06	0.00522	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	8.57e-06	0.0052	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—GRP—head and neck cancer	8.32e-06	0.00504	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—MAPK3—head and neck cancer	8.32e-06	0.00504	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KISS1—head and neck cancer	8.04e-06	0.00488	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—MAPK1—head and neck cancer	7.92e-06	0.0048	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—AKT1—head and neck cancer	7.56e-06	0.00458	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GRP—head and neck cancer	7.55e-06	0.00458	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—KISS1—head and neck cancer	7.49e-06	0.00454	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GRP—head and neck cancer	7.29e-06	0.00442	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CASP8—head and neck cancer	7.13e-06	0.00432	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KISS1—head and neck cancer	6.8e-06	0.00412	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GRP—head and neck cancer	6.62e-06	0.00402	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—HRAS—head and neck cancer	6.35e-06	0.00385	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GRP—head and neck cancer	6.17e-06	0.00374	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—AKT1—head and neck cancer	5.61e-06	0.0034	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GRP—head and neck cancer	5.6e-06	0.00339	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KISS1—head and neck cancer	5.42e-06	0.00329	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL2—head and neck cancer	5.39e-06	0.00327	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	5.29e-06	0.00321	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	5.17e-06	0.00314	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	5.15e-06	0.00312	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KISS1—head and neck cancer	4.75e-06	0.00288	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—UROD—head and neck cancer	4.61e-06	0.0028	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	4.58e-06	0.00278	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GRP—head and neck cancer	4.46e-06	0.00271	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT6—head and neck cancer	4.33e-06	0.00263	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NAT2—head and neck cancer	4.18e-06	0.00253	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KISS1—head and neck cancer	4.02e-06	0.00243	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GRP—head and neck cancer	3.91e-06	0.00237	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—YAP1—head and neck cancer	3.83e-06	0.00232	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT6—head and neck cancer	3.8e-06	0.0023	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—DPYD—head and neck cancer	3.66e-06	0.00222	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	3.52e-06	0.00213	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—YAP1—head and neck cancer	3.48e-06	0.00211	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	3.37e-06	0.00205	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—YAP1—head and neck cancer	3.36e-06	0.00204	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GRP—head and neck cancer	3.31e-06	0.00201	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT6—head and neck cancer	3.21e-06	0.00195	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	3.02e-06	0.00183	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	2.87e-06	0.00174	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—YAP1—head and neck cancer	2.84e-06	0.00172	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	2.59e-06	0.00157	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	2.5e-06	0.00152	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	2.26e-06	0.00137	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2—head and neck cancer	2.22e-06	0.00134	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	2.14e-06	0.0013	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TYMS—head and neck cancer	2.09e-06	0.00127	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—head and neck cancer	2.06e-06	0.00125	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	2.03e-06	0.00123	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	2.03e-06	0.00123	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—head and neck cancer	2.01e-06	0.00122	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPX1—head and neck cancer	1.98e-06	0.0012	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP1A1—head and neck cancer	1.96e-06	0.00119	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—head and neck cancer	1.94e-06	0.00118	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NAT2—head and neck cancer	1.92e-06	0.00116	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—head and neck cancer	1.77e-06	0.00107	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	1.76e-06	0.00107	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH1—head and neck cancer	1.73e-06	0.00105	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	1.71e-06	0.00104	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—DPYD—head and neck cancer	1.68e-06	0.00102	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—head and neck cancer	1.64e-06	0.000996	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK3—head and neck cancer	1.62e-06	0.000981	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—YAP1—head and neck cancer	1.59e-06	0.000967	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK1—head and neck cancer	1.54e-06	0.000934	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—head and neck cancer	1.54e-06	0.000933	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH1—head and neck cancer	1.52e-06	0.000919	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—head and neck cancer	1.49e-06	0.000904	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.47e-06	0.000892	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	1.44e-06	0.000874	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK3—head and neck cancer	1.42e-06	0.00086	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK1—head and neck cancer	1.35e-06	0.000819	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—head and neck cancer	1.35e-06	0.000818	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—head and neck cancer	1.34e-06	0.00081	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.29e-06	0.000782	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH1—head and neck cancer	1.28e-06	0.000776	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRAS—head and neck cancer	1.24e-06	0.00075	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—head and neck cancer	1.2e-06	0.000729	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK3—head and neck cancer	1.2e-06	0.000727	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—head and neck cancer	1.19e-06	0.000721	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—head and neck cancer	1.17e-06	0.00071	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—head and neck cancer	1.16e-06	0.000705	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—head and neck cancer	1.16e-06	0.000703	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK1—head and neck cancer	1.14e-06	0.000692	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—head and neck cancer	1.14e-06	0.000692	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—head and neck cancer	1.12e-06	0.000678	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—head and neck cancer	1.09e-06	0.000662	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.09e-06	0.000661	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRAS—head and neck cancer	1.08e-06	0.000657	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—head and neck cancer	1.05e-06	0.000639	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—head and neck cancer	1.04e-06	0.000632	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—head and neck cancer	1.02e-06	0.000616	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—head and neck cancer	1.01e-06	0.000615	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—head and neck cancer	1.01e-06	0.000613	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—head and neck cancer	1e-06	0.000607	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—head and neck cancer	9.9e-07	0.0006	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—head and neck cancer	9.81e-07	0.000595	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMS—head and neck cancer	9.57e-07	0.00058	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—head and neck cancer	9.57e-07	0.00058	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK3—head and neck cancer	9.56e-07	0.00058	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—head and neck cancer	9.46e-07	0.000574	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRAS—head and neck cancer	9.16e-07	0.000555	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK1—head and neck cancer	9.1e-07	0.000552	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—head and neck cancer	9.09e-07	0.000551	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX1—head and neck cancer	9.06e-07	0.000549	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A1—head and neck cancer	8.97e-07	0.000544	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—head and neck cancer	8.91e-07	0.00054	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—head and neck cancer	8.86e-07	0.000537	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—head and neck cancer	8.81e-07	0.000534	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—head and neck cancer	8.77e-07	0.000532	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—head and neck cancer	8.59e-07	0.000521	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK3—head and neck cancer	8.38e-07	0.000508	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—head and neck cancer	8.29e-07	0.000503	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—head and neck cancer	8.09e-07	0.00049	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK1—head and neck cancer	7.98e-07	0.000484	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—head and neck cancer	7.98e-07	0.000484	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—head and neck cancer	7.89e-07	0.000479	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—head and neck cancer	7.64e-07	0.000463	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—head and neck cancer	7.49e-07	0.000454	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—head and neck cancer	7.42e-07	0.00045	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRAS—head and neck cancer	7.3e-07	0.000443	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—head and neck cancer	7.15e-07	0.000434	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK3—head and neck cancer	7.09e-07	0.00043	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—head and neck cancer	6.92e-07	0.00042	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK1—head and neck cancer	6.74e-07	0.000409	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—head and neck cancer	6.74e-07	0.000409	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—head and neck cancer	6.7e-07	0.000406	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—head and neck cancer	6.45e-07	0.000391	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRAS—head and neck cancer	6.4e-07	0.000388	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—head and neck cancer	5.85e-07	0.000355	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—head and neck cancer	5.84e-07	0.000354	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—head and neck cancer	5.66e-07	0.000343	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—head and neck cancer	5.65e-07	0.000343	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRAS—head and neck cancer	5.41e-07	0.000328	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—head and neck cancer	5.33e-07	0.000323	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—head and neck cancer	4.78e-07	0.00029	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—head and neck cancer	4.65e-07	0.000282	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—head and neck cancer	3.28e-07	0.000199	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—head and neck cancer	2.68e-07	0.000163	CbGpPWpGaD
